Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fulvestrant Alone Versus Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial in Postmenopausal Patients

NCT02137837 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT02137837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02137837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fulvestrant Alone Versus Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial in Postmenopausal Patients
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 3
Overall status
Terminated
Start date
May 31, 2014
Completion date
December 31, 2019
Enrollment
37 (actual)
Sites
223

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer